Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?
Introduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era. Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Mattioli1885
2023-07-01
|
| Series: | Dermatology Practical & Conceptual |
| Subjects: | |
| Online Access: | http://dpcj.org/index.php/dpc/article/view/2912 |
| _version_ | 1827878971000225792 |
|---|---|
| author | Özge Kaya Zeynep Keskinkaya Selda Işık Mermutlu Sevilay Oğuz Kılıç Sevgi Öztürk |
| author_facet | Özge Kaya Zeynep Keskinkaya Selda Işık Mermutlu Sevilay Oğuz Kılıç Sevgi Öztürk |
| author_sort | Özge Kaya |
| collection | DOAJ |
| description |
Introduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era.
Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19 infection.
Methods: In this retrospective study, files of CSU patients using OMZ during the COVID-19 pandemic were reviewed in terms of demographic features, medical history including COVID-19 vaccination status, clinical characteristics, pretreatment laboratory parameters, duration, and dosing regimen of OMZ treatment. Patients with a history of COVID-19 infection while on OMZ therapy and patients without COVID-19 history were compared with respect to these parameters. The urticaria activations following COVID-19 infection or vaccination were also recorded.
Results: Sixty-eight patients with CSU (female:male ratio= 1.8:1; mean age= 47.2 ± 15.1 years) continued to receive OMZ treatment. The median duration of OMZ treatment was 12 months (range: 6-60). Twelve patients (17.6%) were diagnosed with COVID-19 showing no exacerbation in urticaria. The duration of OMZ treatment was significantly higher in the group with COVID-19 infection history compared to patients with no history of COVID-19 (p=0.01). Among 51 patients (75%) vaccinated against COVID-19, urticaria activation occurred in four patients without any recurrence following booster vaccinations.
Conclusions: Considering the likelihood of increased COVID-19 infection risk in the setting of long-term OMZ in CSU patients, the duration of OMZ therapy might be kept at a minimum, or a temporary interruption of the treatment period might be preferred, particularly in high-risk patients regarding COVID-19.
|
| first_indexed | 2024-03-12T18:00:03Z |
| format | Article |
| id | doaj.art-113b4cc78d1046d8a71825167e18f182 |
| institution | Directory Open Access Journal |
| issn | 2160-9381 |
| language | English |
| last_indexed | 2024-03-12T18:00:03Z |
| publishDate | 2023-07-01 |
| publisher | Mattioli1885 |
| record_format | Article |
| series | Dermatology Practical & Conceptual |
| spelling | doaj.art-113b4cc78d1046d8a71825167e18f1822023-08-02T12:23:46ZengMattioli1885Dermatology Practical & Conceptual2160-93812023-07-0113310.5826/dpc.1303a145Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19?Özge Kaya0Zeynep Keskinkaya1Selda Işık Mermutlu2Sevilay Oğuz Kılıç3Sevgi Öztürk4Department of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, TurkeyDepartment of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, TurkeyDepartment of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, TurkeyDepartment of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, TurkeyDepartment of Dermatology and Venereology, Çanakkale Onsekiz Mart University Faculty of Medicine, Çanakkale, Turkey Introduction: Based on the existing literature, omalizumab (OMZ) is considered a safe treatment modality in chronic spontaneous urticaria (CSU) during the coronavirus disease 19 (COVID-19) era. Objectives: The aim of this study is to evaluate the effects of OMZ on CSU patients regarding COVID-19 infection. Methods: In this retrospective study, files of CSU patients using OMZ during the COVID-19 pandemic were reviewed in terms of demographic features, medical history including COVID-19 vaccination status, clinical characteristics, pretreatment laboratory parameters, duration, and dosing regimen of OMZ treatment. Patients with a history of COVID-19 infection while on OMZ therapy and patients without COVID-19 history were compared with respect to these parameters. The urticaria activations following COVID-19 infection or vaccination were also recorded. Results: Sixty-eight patients with CSU (female:male ratio= 1.8:1; mean age= 47.2 ± 15.1 years) continued to receive OMZ treatment. The median duration of OMZ treatment was 12 months (range: 6-60). Twelve patients (17.6%) were diagnosed with COVID-19 showing no exacerbation in urticaria. The duration of OMZ treatment was significantly higher in the group with COVID-19 infection history compared to patients with no history of COVID-19 (p=0.01). Among 51 patients (75%) vaccinated against COVID-19, urticaria activation occurred in four patients without any recurrence following booster vaccinations. Conclusions: Considering the likelihood of increased COVID-19 infection risk in the setting of long-term OMZ in CSU patients, the duration of OMZ therapy might be kept at a minimum, or a temporary interruption of the treatment period might be preferred, particularly in high-risk patients regarding COVID-19. http://dpcj.org/index.php/dpc/article/view/2912angiotensin-converting enzyme 2chronic spontaneous urticaria COVID-19omalizumabactivation |
| spellingShingle | Özge Kaya Zeynep Keskinkaya Selda Işık Mermutlu Sevilay Oğuz Kılıç Sevgi Öztürk Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19? Dermatology Practical & Conceptual angiotensin-converting enzyme 2 chronic spontaneous urticaria COVID-19 omalizumab activation |
| title | Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19? |
| title_full | Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19? |
| title_fullStr | Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19? |
| title_full_unstemmed | Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19? |
| title_short | Long-term Omalizumab Therapy in Patients with Chronic Spontaneous Urticaria: Does it Increase the Risk of COVID-19? |
| title_sort | long term omalizumab therapy in patients with chronic spontaneous urticaria does it increase the risk of covid 19 |
| topic | angiotensin-converting enzyme 2 chronic spontaneous urticaria COVID-19 omalizumab activation |
| url | http://dpcj.org/index.php/dpc/article/view/2912 |
| work_keys_str_mv | AT ozgekaya longtermomalizumabtherapyinpatientswithchronicspontaneousurticariadoesitincreasetheriskofcovid19 AT zeynepkeskinkaya longtermomalizumabtherapyinpatientswithchronicspontaneousurticariadoesitincreasetheriskofcovid19 AT seldaisıkmermutlu longtermomalizumabtherapyinpatientswithchronicspontaneousurticariadoesitincreasetheriskofcovid19 AT sevilayoguzkılıc longtermomalizumabtherapyinpatientswithchronicspontaneousurticariadoesitincreasetheriskofcovid19 AT sevgiozturk longtermomalizumabtherapyinpatientswithchronicspontaneousurticariadoesitincreasetheriskofcovid19 |